Home » Rising Pharmaceuticals Admits Price Fixing
Rising Pharmaceuticals Admits Price Fixing
New Jersey-based generic drugmaker Rising Pharmaceuticals admitted to price fixing for the hypertension drug Benazepril HCTZ and agreed to pay more than $3 million under a deferred prosecution agreement with the Department of Justice.
The DOJ previously entered into a deferred prosecution agreement with Heritage Pharmaceuticals.
The department will hold off on prosecuting Rising for three years, or until the company’s bankruptcy proceedings are completed.
Upcoming Events
-
07May
-
14May
-
30May